Want to join the conversation?
$PFE said it has published new analysis of data from 3 VYNDAQEL studies in patients with mild transthyretin familial amyloid polyneuropathy. The analysis showed that VYNDAQEL treatment during early disease stage resulted in minimal neurological disease progression and in preservation of body weight, which often declines as disease progresses.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.